Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. Finance, is $83.60; the latter earns a price target of $50.80 from ...

研究背景 基因编辑技术的精准化发展极大推动了生命科学研究，并为遗传病治疗提供了强有力的工具。先导编辑（Prime Editing, ...

After hours: February 21 at 7:59:03 p.m. EST ...